Stalevo

DRUG5 trials

Sponsors

Molecular NeuroImaging, Orion Corporation, Orion Pharma, Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

Parkinson DiseaseParkinson's Disease

Phase 2

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

CompletedNCT00200447

Molecular NeuroImagingParkinson's Disease

Start: 2004-03-31End: 2004-09-30Updated: 2008-01-21

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

CompletedNCT01766258

Orion Corporation, Orion PharmaParkinson's Disease

Start: 2011-05-31End: 2012-09-30Updated: 2013-11-21

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

CompletedNCT02764125

Orion Corporation, Orion PharmaParkinson's Disease

Start: 2016-04-08End: 2018-03-27Updated: 2018-04-05

Phase 4

Study to Evaluate Initiation of Stalevo in Early Wearing-off

CompletedNCT00462007

Orion Corporation, Orion PharmaParkinson's Disease

Start: 2006-09-30End: 2007-12-31Updated: 2015-04-21

Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityParkinson Disease

Start: 2022-01-01End: 2023-12-31Target: 180Updated: 2023-02-16

Related Papers

Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.

2019-03-0133 citations